Bruker's Preliminary Q2 Revenues Miss Estimates, Stock Tumbles | GenomeWeb

NEW YORK (GenomeWeb News) – Bruker today announced preliminary second-quarter revenues of $420 million, falling short of analyst estimates of $434.5 million.

The company posted revenues of $401.2 million a year ago. Bruker is scheduled to report its second-quarter earnings on July 31.

Bruker added that EPS for the second quarter is expected to be in the range of $.05 and $.07, while adjusted EPS is expected to fall between $.11 and $.13, which would also miss a consensus Wall Street estimate of $.21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.